vs
Side-by-side financial comparison of Ponce Financial Group, Inc. (PDLB) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
Ponce Financial Group, Inc. is the larger business by last-quarter revenue ($31.4M vs $18.6M, roughly 1.7× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs 36.3%, a 29.5% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 37.6%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 23.7%).
Ponce Financial Group, Inc. is a U.S.-based financial holding company operating Ponce Bank as its core subsidiary. It serves multicultural, immigrant and low-to-moderate income communities in the New York metro area, offering retail and commercial banking products including deposits, mortgages, small business financing and personal credit.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
PDLB vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $31.4M | $18.6M |
| Net Profit | $10.1M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | 43.6% | 56.3% |
| Net Margin | 36.3% | 65.7% |
| Revenue YoY | 37.6% | 1808.5% |
| Net Profit YoY | 245.6% | 376.5% |
| EPS (diluted) | $0.43 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $31.4M | $18.6M | ||
| Q3 25 | $26.7M | $334.0K | ||
| Q2 25 | $26.5M | $1.4M | ||
| Q1 25 | $24.6M | $257.0K | ||
| Q4 24 | $22.8M | $977.0K | ||
| Q3 24 | $20.2M | $660.0K | ||
| Q2 24 | $20.2M | $736.0K | ||
| Q1 24 | $20.5M | $1.4M |
| Q4 25 | $10.1M | $12.3M | ||
| Q3 25 | $6.5M | $-8.6M | ||
| Q2 25 | $6.1M | $-6.9M | ||
| Q1 25 | $6.0M | $-5.4M | ||
| Q4 24 | $2.9M | — | ||
| Q3 24 | $2.4M | $-2.8M | ||
| Q2 24 | $3.2M | $-14.5M | ||
| Q1 24 | $2.4M | $411.0K |
| Q4 25 | 43.6% | 56.3% | ||
| Q3 25 | 32.8% | -2516.5% | ||
| Q2 25 | 30.2% | -701.0% | ||
| Q1 25 | 32.5% | -3350.2% | ||
| Q4 24 | 19.6% | — | ||
| Q3 24 | 15.2% | -1563.6% | ||
| Q2 24 | 21.8% | -1255.0% | ||
| Q1 24 | 18.3% | -692.5% |
| Q4 25 | 36.3% | 65.7% | ||
| Q3 25 | 24.3% | -2572.2% | ||
| Q2 25 | 23.0% | -504.8% | ||
| Q1 25 | 24.2% | -2097.7% | ||
| Q4 24 | 14.1% | — | ||
| Q3 24 | 12.1% | -425.5% | ||
| Q2 24 | 15.8% | -1964.4% | ||
| Q1 24 | 11.8% | 29.9% |
| Q4 25 | $0.43 | $0.25 | ||
| Q3 25 | $0.27 | $-0.17 | ||
| Q2 25 | $0.25 | $-0.14 | ||
| Q1 25 | $0.25 | $-0.11 | ||
| Q4 24 | $0.11 | — | ||
| Q3 24 | $0.10 | $-0.06 | ||
| Q2 24 | $0.14 | $-0.30 | ||
| Q1 24 | $0.11 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $126.2M | $40.0M |
| Total DebtLower is stronger | $596.1M | — |
| Stockholders' EquityBook value | $541.5M | $49.4M |
| Total Assets | $3.2B | $59.0M |
| Debt / EquityLower = less leverage | 1.10× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $126.2M | $40.0M | ||
| Q3 25 | $146.6M | $37.9M | ||
| Q2 25 | $126.6M | $44.8M | ||
| Q1 25 | $129.9M | $40.6M | ||
| Q4 24 | $139.8M | $59.3M | ||
| Q3 24 | $155.8M | $68.8M | ||
| Q2 24 | $103.2M | $73.0M | ||
| Q1 24 | $134.7M | $80.2M |
| Q4 25 | $596.1M | — | ||
| Q3 25 | $521.1M | — | ||
| Q2 25 | $536.1M | — | ||
| Q1 25 | $521.1M | — | ||
| Q4 24 | $596.1M | — | ||
| Q3 24 | $580.4M | — | ||
| Q2 24 | $680.4M | — | ||
| Q1 24 | $680.4M | — |
| Q4 25 | $541.5M | $49.4M | ||
| Q3 25 | $529.8M | $36.4M | ||
| Q2 25 | $521.1M | $44.5M | ||
| Q1 25 | $513.9M | $50.5M | ||
| Q4 24 | $505.5M | $55.1M | ||
| Q3 24 | $504.6M | $58.5M | ||
| Q2 24 | $497.7M | $60.4M | ||
| Q1 24 | $493.7M | $74.1M |
| Q4 25 | $3.2B | $59.0M | ||
| Q3 25 | $3.2B | $51.1M | ||
| Q2 25 | $3.2B | $60.7M | ||
| Q1 25 | $3.1B | $67.9M | ||
| Q4 24 | $3.0B | $90.6M | ||
| Q3 24 | $3.0B | $99.0M | ||
| Q2 24 | $2.8B | $107.8M | ||
| Q1 24 | $2.8B | $118.3M |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 0.98× | — | ||
| Q2 25 | 1.03× | — | ||
| Q1 25 | 1.01× | — | ||
| Q4 24 | 1.18× | — | ||
| Q3 24 | 1.15× | — | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 1.38× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $55.6M | $18.4M |
| Free Cash FlowOCF − Capex | $54.6M | — |
| FCF MarginFCF / Revenue | 173.9% | — |
| Capex IntensityCapex / Revenue | 3.1% | — |
| Cash ConversionOCF / Net Profit | 5.48× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $74.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $55.6M | $18.4M | ||
| Q3 25 | $1.4M | $-8.7M | ||
| Q2 25 | $6.2M | $-7.5M | ||
| Q1 25 | $13.1M | $-7.5M | ||
| Q4 24 | $7.2M | $-24.0M | ||
| Q3 24 | $-14.6M | $765.0K | ||
| Q2 24 | $-2.6M | $-10.9M | ||
| Q1 24 | $1.5M | $-4.0M |
| Q4 25 | $54.6M | — | ||
| Q3 25 | $786.0K | — | ||
| Q2 25 | $5.9M | — | ||
| Q1 25 | $12.9M | — | ||
| Q4 24 | $4.5M | — | ||
| Q3 24 | $-15.0M | — | ||
| Q2 24 | $-2.6M | — | ||
| Q1 24 | $-315.0K | — |
| Q4 25 | 173.9% | — | ||
| Q3 25 | 2.9% | — | ||
| Q2 25 | 22.4% | — | ||
| Q1 25 | 52.6% | — | ||
| Q4 24 | 19.7% | — | ||
| Q3 24 | -74.1% | — | ||
| Q2 24 | -13.0% | — | ||
| Q1 24 | -1.5% | — |
| Q4 25 | 3.1% | — | ||
| Q3 25 | 2.3% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 0.6% | — | ||
| Q4 24 | 11.9% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | 8.7% | — |
| Q4 25 | 5.48× | 1.50× | ||
| Q3 25 | 0.21× | — | ||
| Q2 25 | 1.01× | — | ||
| Q1 25 | 2.20× | — | ||
| Q4 24 | 2.46× | — | ||
| Q3 24 | -5.99× | — | ||
| Q2 24 | -0.80× | — | ||
| Q1 24 | 0.61× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PDLB
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
